274 related articles for article (PubMed ID: 28608116)
1. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
2. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
[TBL] [Abstract][Full Text] [Related]
3. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
4. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
[TBL] [Abstract][Full Text] [Related]
5. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
6. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
7. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
[TBL] [Abstract][Full Text] [Related]
9. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
11. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
[TBL] [Abstract][Full Text] [Related]
12. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
13. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
Iwazawa T; Kawanishi K; Fujita J; Takata A; Hirota M; Imamura H; Ikeda A; Hokonohara K; Yoneyama C; Kameyama A; Shinke G; Oshima K; Tanida T; Hatano H; Noda T; Komori T; Morita S; Akagi K; Dono K
Gan To Kagaku Ryoho; 2015 Aug; 42(8):957-60. PubMed ID: 26321709
[TBL] [Abstract][Full Text] [Related]
14. Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.
Tanahashi T; Yoshida K; Yamaguchi K; Okumura N; Takeno A; Fujitani K; Fukushima N; Takiguchi N; Nishida Y; Boku N; Yoshikawa T; Terashima M
Gastric Cancer; 2019 Jan; 22(1):130-137. PubMed ID: 29799059
[TBL] [Abstract][Full Text] [Related]
15. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
[TBL] [Abstract][Full Text] [Related]
17. [Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2289-91. PubMed ID: 24394088
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
[TBL] [Abstract][Full Text] [Related]
20. Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis.
Iizuka A; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2019 Aug; 43(8):2016-2024. PubMed ID: 30737551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
